Lilly adds $4.5 billion to Indiana manufacturing to boost weight-loss drug supply

Eli Lilly & Co. announced an additional $4.5 billion investment in two of its three manufacturing sites in Lebanon, Indiana. The funding is aimed at expanding capacity for both its genetic therapies and its growing portfolio of weight‑loss medicines.

The company plans to introduce new process designs and technologies at the active pharmaceutical ingredient (API) factory that is slated to open next year. This includes the capability to produce Foundayo, Lilly's first FDA‑approved once‑daily oral weight‑loss pill.

With the new spend, Lilly's total capital expansion commitments in Indiana exceed $21 billion over the past six years. The move reflects a broader reshoring trend, as the firm has poured billions into domestic facilities to meet rising demand for injectable and oral weight‑loss treatments.